the Nontuberculous Mycobacteria Infections Treatment Market Size in the 7MM was more than USD 750 million in 2025 and It is projected to grow at a CAGR of 12.6% by 2036

(Albany, US) On October 08, 2026, DelveInsight’s “Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.

Discover Key Insights into the Nontuberculous Mycobacterial Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market

Key Takeaways from the Nontuberculous Mycobacterial Market Report

• On October 08, 2026 – MicuRx Pharmaceuticals announced that the FDA cleared its Investigational New Drug (IND) application for MRX-5, paving the way for a Phase IIa clinical trial evaluating the investigational therapy in patients with Mycobacterium abscessus pulmonary disease, a difficult-to-treat form of nontuberculous mycobacterial (NTM) infection.
• In August 2026, researchers from the National Tuberculosis Institute and collaborating Indian medical centers evaluated a multiplex real-time PCR assay for the simultaneous detection of Mycobacterium tuberculosis, NTM, and drug resistance.
• In 2025, the total number of diagnosed prevalent cases of Nontuberculous Mycobacteria Infections in the 7MM was around 400,000. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases, contributing approximately 125,000 cases.
• According to DelveInsight analysis, more than 40,000 males and 80,000 females were affected with NTM infections in the US in 2025, depicting a clear gender disparity due to hormonal factors.
• M. avium remains the most prevalent causative species across EU4 and the UK, accounting for approximately 70,000 diagnosed prevalent cases in 2025. In comparison, M. abscessus represents a smaller yet clinically significant proportion, with more than 17,000 diagnosed prevalent cases, while other NTM species collectively contribute around 120,000 cases.
• According to DelveInsight’s analysis, moderate NTM infections constituted the largest proportion of diagnosed cases across EU4 and the UK in 2025, with approximately 115,000 cases, followed by mild (70,000) and severe (26,000) cases.
• Pulmonary NTM infections accounted for the majority of diagnosed prevalent cases in Japan in 2025, with approximately 60,000 cases, compared with approximately 6,500 cases of extrapulmonary NTM infections.
• In 2025, Japan reported approximately 8,000 refractory cases of NTM infections. The growing burden of refractory disease is largely attributable to the prolonged duration and complexity of NTM treatment, where extended multidrug regimens are frequently associated with treatment discontinuation, adverse events, and incomplete microbiological clearance.
• The leading Nontuberculous Mycobacterial Companies such as Insmed, Paratek Pharmaceuticals, MicuRx Pharmaceuticals, Vast Therapeutics, BioVersys, AN2 Therapeutics and others.
• Promising Nontuberculous Mycobacterial Therapies such as SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others.

Stay ahead in the Nontuberculous Mycobacterial Therapeutics Market with DelveInsight’s Strategic Report @ Nontuberculous Mycobacterial Market Outlook

Nontuberculous Mycobacteria Infections Overview

NTM infections are diseases caused by bacteria in the genus Mycobacterium, excluding those that cause Tuberculosis (M. tuberculosis complex) or leprosy/Hansen’s disease (M. leprae). The main risk factors for NTM infection include pre-existing lung disease, reduced ciliary function, heterozygosity for mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene, breaches in the skin or soft tissues, and immunodeficiency. Environmental factors, such as water sources and reservoirs, and NTM growth characteristics under different climatic conditions also contribute to risk.

Nontuberculous Mycobacterial Epidemiology Segmentation in the 7MM

• Total Nontuberculous Mycobacteria Infections Diagnosed Prevalent Cases
• Nontuberculous Mycobacteria Infections Gender-specific Diagnosed Prevalent Cases
• Nontuberculous Mycobacteria Infections Species-specific Diagnosed Prevalent Cases
• Nontuberculous Mycobacteria Infections Severity-specific Diagnosed Prevalent Cases
• Nontuberculous Mycobacteria Infections Type-specific Diagnosed Prevalent Cases
• Total Nontuberculous Mycobacteria Infections Treated Cases
• Nontuberculous Mycobacteria Infections Refractory Cases

Download the report to understand which factors are driving Nontuberculous Mycobacterial epidemiology trends @ Nontuberculous Mycobacterial Prevalence

Nontuberculous Mycobacteria Infections Approved Therapies

• Amikacin Liposome Inhalation Suspension (ARIKAYCE): Insmed

ARIKAYCE is the first FDA-approved therapy indicated for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function.

Nontuberculous Mycobacteria Infections Pipeline Analysis

• Omadacycline (NUZYRA): Paratek Pharmaceuticals

NUZYRA, developed by Paratek Pharmaceuticals, is a novel antibiotic currently in Phase II of clinical development for the treatment of NTM pulmonary disease M. abscessus complex (MABc). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including gram-positive, gram-negative, atypical, and other drug-resistant strains

Get In-Depth Knowledge on Nontuberculous Mycobacterial Market Trends and Forecasts with DelveInsight @ Nontuberculous Mycobacterial Treatment Market

Nontuberculous Mycobacteria Infections Market Outlook

Treatment practices remain heterogeneous in NTM infections despite established ATS/ERS/ESCMID/IDSA guidelines, with considerable geographic variation in physician testing, treatment initiation, and access to specialized mycobacteriology laboratories. Current management of NTM-PD relies on prolonged multidrug antibiotic regimens regimens selected according to infecting species, antimicrobial susceptibility, disease severity, and treatment tolerance administered for at least 12 months after sputum culture conversion, often resulting in treatment durations exceeding 18 months. These complex regimens are associated with substantial pill burden, frequent adverse events, and poor treatment adherence, contributing to low culture conversion rates, high recurrence, and the emergence of antimicrobial resistance.

Unlock Strategic Insights with DelveInsight’s Comprehensive Nontuberculous Mycobacterial Market Report @ Nontuberculous Mycobacterial Market Drivers and Barriers

Scope of the Nontuberculous Mycobacterial Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Nontuberculous Mycobacterial Companies- Insmed, Paratek Pharmaceuticals, MicuRx Pharmaceuticals, Vast Therapeutics, BioVersys, AN2 Therapeutics and others
• Nontuberculous Mycobacterial Therapies- SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others
• Nontuberculous Mycobacterial Therapeutic Assessment: Nontuberculous Mycobacterial current marketed and Nontuberculous Mycobacterial emerging therapies
• Nontuberculous Mycobacterial Market Dynamics: Nontuberculous Mycobacterial market drivers and Nontuberculous Mycobacterial market barriers
• Nontuberculous Mycobacterial Unmet Needs, KOL’s views, Analyst’s views, Nontuberculous Mycobacterial Market Access and Reimbursement

Table of Content

1. Key Insights
2. Report Introduction
3. NTM Infection Market Overview at a Glance
4. Nontuberculous Mycobacterial Epidemiology and Market Forecast Methodology
5. Nontuberculous Mycobacterial Executive Summary
6. Key Events
7. Nontuberculous Mycobacterial Disease Background and Overview
8. Nontuberculous Mycobacterial Patient Journey
9. Nontuberculous Mycobacterial Epidemiology and Patient Population
10. Nontuberculous Mycobacterial Marketed Drugs
11. Nontuberculous Mycobacterial Emerging Drugs
12. Nontuberculous Mycobacterial Infections: Market Analysis
13. Key Opinion Leaders’ Views
14. Nontuberculous Mycobacterial SWOT Analysis
15. Nontuberculous Mycobacterial Unmet Needs
16. Nontuberculous Mycobacterial Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market